13
Participants
Start Date
November 30, 2003
Primary Completion Date
January 31, 2010
Study Completion Date
February 17, 2012
Alemtuzumab i.v.
"Alemtuzumab will be administered once per week as a 2 h infusion~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
Alemtuzumab s.c.
"Alemtuzumab will be administered once per week subcutaneously~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
Klinikum Barnim GmbH, Werner Forssmann Krankenhaus, Eberswalde
Medizinische Universitaetsklinik I at the University of Cologne, Cologne
Universitatsklinikum Heidelberg, Heidelberg
Klinikum Lippe - Lemgo, Lemgo
III Medizinische Klinik Mannheim, Mannheim
Krankenhaus Barmherzige Brueder Regensburg, Regensburg
German CLL Study Group
OTHER